HIPEC Treatment for Ovarian Cancer in IndiaThe Complete Patient Guide — What It Is, How It Works, Cost, Eligibility & Risk
Hyperthermic Intraperitoneal Chemotherapy | Cytoreductive Surgery | OVHIPEC-1 Trial | Complete Procedure & ICU Recovery Guide
⭐ Key Facts at a Glance — HIPEC for Ovarian Cancer
In 2018, the New England Journal of Medicine — the world's most prestigious medical journal — published a trial that changed the way advanced ovarian cancer is treated. The OVHIPEC-1 trial, from the Netherlands Cancer Institute, showed that adding HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to standard debulking surgery for Stage III ovarian cancer extended median overall survival by approximately 12 months — without significantly increasing serious complications. In a disease where treatment advances are measured in months, this was a landmark result.
HIPEC is not a new drug. It is not a new chemotherapy. It is a fundamentally different way of delivering chemotherapy — directly into the abdominal cavity at elevated temperature, immediately after surgery removes all visible cancer, targeting the microscopic deposits that surgery cannot see. The concept is elegant: ovarian cancer spreads primarily along the peritoneum (the lining of the abdominal cavity), and conventional IV chemotherapy reaches the peritoneum at relatively low concentrations. HIPEC bypasses this limitation — delivering drug concentrations at the peritoneal surface that are 10–1,000 times higher than any IV regimen could achieve.
How to Use This Guide
This guide gives every ovarian cancer patient and her family the knowledge to understand HIPEC — its mechanism, its evidence, its eligibility criteria, its detailed procedure, the post-operative ICU journey, the cost in India, and why the team at Shree Hospitals is uniquely qualified to perform it. Whether you are reading this before your diagnosis is confirmed, while navigating NACT, or approaching interval debulking surgery — this guide has the answers.
To understand why HIPEC works — and why it works specifically for ovarian cancer — it helps to understand how ovarian cancer spreads and why conventional treatment has a fundamental limitation.
Ovarian cancer spreads primarily through a process called peritoneal dissemination. Cancer cells shed from the ovarian tumour are carried by the normal circulation of peritoneal fluid throughout the abdominal cavity. They implant on the peritoneal surfaces — the serosal lining of the bowel, the surface of the liver, the diaphragm, the pelvic sidewalls, and the omentum — forming millions of microscopic cancer deposits too small to see, feel, or remove surgically.
Conventional IV chemotherapy reaches these peritoneal deposits at relatively low drug concentrations — because of what is called the peritoneal-plasma barrier: the peritoneal lining limits how much drug from the bloodstream can enter the peritoneal cavity. This is one reason why, despite high initial response rates to IV carboplatin + paclitaxel, ovarian cancer recurs in the majority of patients — from the microscopic peritoneal deposits that survived chemotherapy.
HIPEC addresses this limitation directly. By delivering chemotherapy into the peritoneal cavity rather than the bloodstream, it achieves drug concentrations at the peritoneal surface that are orders of magnitude higher than anything achievable by IV delivery. The addition of heat amplifies this effect — the elevated temperature (41–43°C) directly kills cancer cells, increases cellular permeability to drugs, and synergistically enhances chemotherapy cytotoxicity.
| Feature | Standard IV Chemotherapy | HIPEC (Hyperthermic Intraperitoneal) |
|---|---|---|
| Route of delivery | Intravenous — drug enters the bloodstream and is distributed throughout the body | Directly into the abdominal (peritoneal) cavity through surgical drains/catheters — drug stays concentrated in the abdomen |
| Drug concentration at peritoneum | Low — the peritoneal-plasma barrier significantly limits how much IV chemotherapy reaches the peritoneum. Only a small fraction of the IV dose reaches peritoneal surfaces. | Extremely high — 10 to 1,000 times higher drug concentration at the peritoneal surface compared to IV delivery. This dramatically increased exposure is the key therapeutic mechanism. |
| Systemic side effects | High — the drug circulates throughout the body, affecting bone marrow, kidneys, and nervous system | Lower systemic side effects overall — however, cisplatin (the most common HIPEC drug) does cause renal toxicity |
| Role of Heat (Hyperthermia) | Not applicable | Three independent effects: direct cytotoxic effect on cancer cells (heat kills cells by denaturing proteins); enhanced drug penetration into tumour tissue; and increased sensitivity of cancer cells to chemotherapy damage |
| Drug penetration into tumour | Limited to surface of tumour deposits | Heated chemotherapy penetrates to approximately 3–5mm depth into tumour tissue — reaching microscopic deposits that surgery cannot remove |
| Timing relative to surgery | Given weeks to months after surgery or before surgery (NACT) | Given immediately after surgery, in the same operative session, while the abdomen is still open — targeting residual microscopic disease before it can establish new implants |
| Duration | Multiple infusion sessions over months (6 cycles = 18 weeks for carboplatin/paclitaxel) | Single 90-minute perfusion intraoperatively — one exposure delivers a massive targeted dose |
| Primary target | Systemic disease — lymph nodes, blood-borne metastases, and peritoneal disease (indirectly) | Peritoneal disease specifically — microscopic peritoneal deposits that are the primary pattern of ovarian cancer spread |
HIPEC is one of the most demanding procedures in all of oncology — for both patient and surgical team. It requires cytoreductive surgery lasting 4–10 hours, the expertise of a specialist peritoneal oncosurgeon, a complex intraoperative perfusion protocol, and 7–14 days of intensive post-operative management. The quality of the outcome is directly proportional to the experience of the team performing it.
The Non-Negotiable Rule of HIPEC
A surgeon who cannot achieve complete cytoreduction (CC-0 or CC-1) should not attempt HIPEC. HIPEC administered to a patient with significant residual disease does not improve outcomes — and exposes the patient to the full complication profile of HIPEC without the therapeutic benefit. Patient selection and surgical completeness are as important as the HIPEC technique itself.
| Trial Name | Patient Population | Key Results | Clinical Significance |
|---|---|---|---|
| OVHIPEC-1 (van Driel et al., NEJM 2018) | Stage III epithelial ovarian cancer at interval debulking surgery after NACT. 245 patients randomised. | CRS + HIPEC (cisplatin) vs CRS alone. Median PFS: 14.2 vs 10.7 months (HR 0.66). Median OS: 45.7 vs 33.9 months (+12 months). No significant difference in serious complications. | Landmark trial that established HIPEC as a valid option at IDS for Stage III ovarian cancer. Changed practice internationally. HIPEC is now endorsed by ESGO, NCCN, and other major guidelines. |
| OVHIPEC-2 (Ongoing — Netherlands) | Stage III ovarian cancer at primary debulking surgery (PDS). Currently enrolling. | RCT comparing CRS + HIPEC vs CRS alone at PDS. | Results awaited. Will definitively answer whether HIPEC benefit applies at PDS, not just IDS. Expected to complete 2025–2026. |
| PRODIGE-7 (Quenet et al., Lancet Oncology 2021) | Colorectal peritoneal metastases — NOT ovarian cancer. 265 patients. | CRS ± HIPEC (oxaliplatin). No survival benefit with HIPEC in colorectal peritoneal metastases (contrary to OVHIPEC-1 result in ovarian cancer). | Highlighted that HIPEC benefit may be cancer-type specific. The positive ovarian cancer trial (OVHIPEC-1) vs negative colorectal trial (PRODIGE-7) emphasises that HIPEC should not be considered a generic 'peritoneal cancer treatment' — its benefit is strongest in chemosensitive malignancies like ovarian cancer. |
| CHIPOR (French Trial — Recurrent Ovarian Cancer) | Platinum-sensitive recurrent ovarian cancer at secondary cytoreduction. 434 patients. | CRS ± HIPEC. Results showed HIPEC did not improve PFS in unselected recurrent ovarian cancer. However, subgroup analyses suggest benefit in CC-0 achieved cases. | Emphasises the critical importance of patient selection. Complete cytoreduction before HIPEC is the determinant of benefit — not HIPEC alone. |
Not every ovarian cancer patient is a candidate for HIPEC — and the selection of appropriate patients is as important as the surgical technique itself. At Shree Hospitals, HIPEC eligibility assessment is performed jointly by Dr. Jay Mehta (Gynecologic Oncology) and Dr. Kaustubh Burde (Advanced Pelvic Surgery) — a two-specialist assessment that evaluates both the oncological appropriateness and the surgical feasibility of HIPEC in each individual patient.
| Eligibility Criterion | Requirement Level | Clinical Details |
|---|---|---|
| Stage III Epithelial Ovarian Cancer | IDEAL — Main indication | Stage III ovarian cancer (disease spread to the peritoneum) is the primary indication established by the OVHIPEC-1 trial. Whether performed at primary debulking surgery (PDS) or at interval debulking surgery (IDS) after NACT, Stage III is the strongest indication for HIPEC. |
| Complete or Near-Complete Cytoreduction (CC-0 or CC-1) | REQUIRED — Non-negotiable prerequisite | HIPEC only works when there is minimal residual disease for it to target. CC-0 (no visible residual disease) is the goal. CC-1 (residual nodules <2.5mm) may be acceptable at some centres. HIPEC should NOT be performed when significant macroscopic disease remains. |
| Good Performance Status (ECOG 0–1) | REQUIRED — Patient fitness | HIPEC is a prolonged, major procedure combining cytoreductive surgery (4–10 hours) with HIPEC perfusion (90 minutes). Total operative time may be 6–12+ hours. The patient must have adequate cardiac, pulmonary, renal, and hepatic reserve to tolerate this extended anaesthetic and surgical exposure. |
| Adequate Organ Function | REQUIRED — Pre-operative assessment | Renal function (creatinine, GFR) — cisplatin (main HIPEC drug) is nephrotoxic; adequate renal reserve essential. Cardiac function — prolonged surgery and fluid shifts require a sound cardiovascular reserve. Bone marrow reserve — adequate haematological indices needed for recovery. |
| Platinum-Sensitive Disease | FAVOURABLE — Better response predicted | The most commonly used HIPEC drug is cisplatin (a platinum compound). Patients with platinum-sensitive disease or chemotherapy-naive disease are most likely to benefit. Platinum-resistant ovarian cancer may have reduced benefit from cisplatin-based HIPEC. |
| Stage IIIC with PCI Assessment | SELECT CASES — Higher PCI limits feasibility | PCI is a quantitative score (0–39) measuring the extent of peritoneal disease. PCI <10–15 is generally associated with achievable complete cytoreduction and favourable HIPEC outcomes. PCI 15–20 may still be feasible at experienced centres. PCI >20 often precludes complete cytoreduction. |
| Stage IV (Pleural Effusion Only — Stage IVA) | SELECTED CASES — Discuss individually | Stage IVA (pleural effusion with cancer cells, no parenchymal organ metastases) may be considered for HIPEC at some centres. Stage IVB (liver/spleen parenchymal metastases, distant lymph nodes) generally does not benefit from HIPEC. |
The table below provides the most detailed description of the HIPEC procedure available in plain language — covering every phase from pre-operative preparation through intraoperative monitoring to abdominal closure. This level of detail allows patients and families to fully understand and mentally prepare for what the procedure involves.
Pre-Operative Planning (Days Before Surgery)
Complete staging CT + MRI abdomen/pelvis to assess PCI and disease distribution. Laparoscopic assessment of resectability (diagnostic laparoscopy) may be performed 1–4 weeks before planned cytoreduction + HIPEC — confirming that complete cytoreduction is achievable before committing to the open procedure. Bowel preparation, central venous catheter and arterial line placed for haemodynamic monitoring. Stoma planning discussion with stoma nurse if bowel resection is anticipated.
Anaesthetic Preparation and Monitoring (Induction Phase)
A specialist cardiac anaesthetist with HIPEC experience is essential. Anaesthetic monitoring for a HIPEC case includes: Standard monitoring (ECG, pulse oximetry, NIBP); Invasive arterial line (radial artery — for continuous blood pressure and arterial blood gas sampling); Central venous catheter (for CVP monitoring and drug delivery); Urinary catheter (hourly urine output — critical for renal protection during cisplatin HIPEC); Temperature probes (typically 3–4 separate probes in the oesophagus, nasopharynx, abdominal wall, and HIPEC circuit); Cardiac output monitoring (PICCO or pulmonary artery catheter in very high-risk cases).
Cytoreductive Surgery Phase (CRS — 4–10 Hours)
The cytoreductive surgery is performed first — before HIPEC is administered. Complete or near-complete removal of all visible cancer is the non-negotiable prerequisite. Typical cytoreductive procedures include: Bilateral salpingo-oophorectomy + hysterectomy; Total omentectomy; Peritoneal stripping (surgical removal of the peritoneal lining from the pelvic sidewalls, bladder dome, diaphragmatic surfaces, and retroperitoneum); Bowel resection + anastomosis (if bowel is involved); Splenectomy (if splenic hilum deposits); Diaphragm stripping or resection; Appendicectomy (routinely performed); Cholecystectomy (if gall bladder involved). Each organ procedure is individually assessed — no more is removed than is needed to achieve complete cytoreduction.
Completeness of Cytoreduction Score (CC Score — Assessed Before HIPEC)
After all cytoreductive procedures are completed, the surgeon performs a final systematic abdominal survey to confirm the CC score: CC-0: No visible residual disease anywhere in the abdomen — the ideal target. CC-1: Residual nodules ≤2.5mm — may be acceptable for HIPEC at experienced centres. CC-2: Residual nodules 2.5mm–2.5cm — HIPEC benefit is significantly reduced. CC-3: Residual disease >2.5cm — HIPEC should NOT be performed. If HIPEC is planned and CC-0/1 is not achieved — a clear intraoperative team discussion must occur about whether to proceed with HIPEC.
HIPEC Machine Setup and Circuit Preparation
While the surgical team completes the final steps of cytoreduction, the perfusionist sets up the HIPEC circuit: The HIPEC machine (e.g., Performer LRT — a dedicated closed-circuit perfusion system) is connected and primed with normal saline. Silicone HIPEC catheters (4–6 in total) are placed through the abdominal wall: Inflow catheters (typically 2): Large-bore drains through which the heated chemotherapy solution enters the abdominal cavity. Outflow catheters (typically 2–3): Large-bore drains through which the fluid drains out back to the HIPEC machine. A temperature probe catheter is placed to measure intraperitoneal temperature in real time.
HIPEC Perfusion Phase (90 Minutes — The Critical Phase)
Phase 1 — Heating (15–20 min): Saline is circulated through the HIPEC circuit and heated to the target temperature (41–43°C intraperitoneal). Phase 2 — Drug loading: Cisplatin (75–100 mg/m² — the most commonly used regimen in ovarian cancer, based on the OVHIPEC-1 protocol) is added to the heated saline. The total circuit volume is typically 2–3 litres. Phase 3 — Active perfusion (60–90 minutes): The heated cisplatin solution circulates continuously through the closed circuit. The surgeon manually agitates the abdomen to ensure uniform distribution of the chemotherapy solution to all peritoneal surfaces. Temperature is maintained at 41–43°C throughout.
Intraoperative Monitoring During HIPEC Perfusion
Continuous monitoring throughout the 90-minute perfusion: Intraperitoneal temperature: 41–43°C target — checked every 5 minutes. Systemic core temperature: monitored at oesophageal/nasopharyngeal probes — must not exceed 38.5°C. Blood pressure: continuously via arterial line. Heart rate and rhythm: ECG monitoring. Urine output: target >1 mL/kg/hour throughout HIPEC — renal protection from cisplatin nephrotoxicity. Aggressive IV hydration (1–2 litres/hour during HIPEC) to maintain urine output. Sodium bicarbonate infusion: urinary alkalinisation to protect kidney tubules from cisplatin precipitation.
Abdominal Washout and Closure (Post-HIPEC Phase)
After 90 minutes of HIPEC perfusion, the circuit is disconnected. The chemotherapy solution is completely drained from the abdominal cavity. Copious warm saline washout (typically 3–6 litres) removes residual chemotherapy drug and any surgical debris. The perfusion catheters are removed. Haemostasis (bleeding control) is confirmed throughout the abdomen. Bowel anastomoses (if performed) are tested for integrity using air insufflation or methylene blue instillation. Drains are placed as appropriate. The abdominal wound is closed in layers. The procedure is now complete.
| HIPEC Drug | Dose and Protocol | Clinical Notes and Selection Rationale |
|---|---|---|
| Cisplatin (Platinum compound) | 75–100 mg/m² Temperature: 41–42°C Duration: 60–90 minutes | The most commonly used HIPEC drug in ovarian cancer — specifically validated in the OVHIPEC-1 trial protocol. Advantages: excellent evidence base, high peritoneal penetration, synergy with hyperthermia, effective against high-grade serous ovarian cancer (inherently platinum-sensitive). Limitations: nephrotoxicity (kidney damage — the primary dose-limiting toxicity), ototoxicity, neuropathy. Requires aggressive renal protection protocol (hydration + alkalinisation). |
| Carboplatin (Platinum compound) | AUC 5–6 Temperature: 41–42°C Duration: 90 minutes | An alternative platinum compound — with lower nephrotoxicity than cisplatin and equivalent anti-tumour activity. Increasingly used in centres preferring to reduce nephrotoxicity risk. Less clinical trial data for HIPEC compared to cisplatin in ovarian cancer. Some centres use carboplatin in patients with pre-existing renal impairment where cisplatin's nephrotoxic risk is unacceptable. |
| Cisplatin + Doxorubicin (Combination) | Cisplatin 75 mg/m² + Doxorubicin 15 mg/m² Temperature: 41–43°C | A two-drug HIPEC combination used at some centres. Adding doxorubicin provides additional cytotoxic mechanisms. Increased systemic toxicity compared to cisplatin alone. Expert centres individualise the HIPEC drug choice based on patient factors and institutional experience. |
| Oxaliplatin | Colorectal cancer peritoneal metastases — NOT standard for ovarian cancer | Oxaliplatin is the primary HIPEC drug for colorectal peritoneal metastases. It is generally NOT used for ovarian cancer HIPEC. HIPEC protocols are tumour-specific. |
| Mitomycin C | Appendiceal cancer (pseudomyxoma peritonei) — occasionally ovarian | Mitomycin C is the standard HIPEC drug for appendiceal mucinous tumours and pseudomyxoma peritonei. Less commonly used for ovarian cancer. Specialised centres may use it in selected mucinous ovarian carcinoma cases. |
The post-operative ICU period after HIPEC is as important as the surgery itself. The combination of a 6–12 hour operation, major fluid shifts, cisplatin nephrotoxicity, bone marrow suppression from chemotherapy, and the physiological stress of hyperthermia creates a complex multi-system management challenge that requires a dedicated, experienced ICU team.
| ICU Domain | Monitoring and Targets | Clinical Details and Rationale |
|---|---|---|
| Cardiovascular Monitoring | Continuous 24–48 hour ICU monitoring: Invasive arterial line; CVP monitoring; Fluid balance (hourly input/output charting); Cardiac output monitoring if haemodynamically unstable | The HIPEC procedure involves large fluid shifts from the peritoneal cavity; protein loss from peritoneal washout; vasodilation from hyperthermia; and blood loss from CRS. Aggressive fluid resuscitation (crystalloid + colloid) is required. Target MAP >65 mmHg. If vasopressor support (noradrenaline) is needed — this indicates significant systemic response and requires intensive management. |
| Renal Protection (Cisplatin Nephroprotection) | Aggressive IV hydration — typically 250–500 mL/hr for the first 12–24 hours; Hourly urine output monitoring — target >1 mL/kg/hour; Urinary alkalinisation with sodium bicarbonate; Daily renal function from day 1; Electrolyte replacement (potassium, magnesium — both depleted by cisplatin) | Cisplatin is directly toxic to renal tubules — the most important organ-specific risk of cisplatin-HIPEC. Prevention: high urine flow (hydration), urinary alkalinisation (makes cisplatin more soluble), and avoidance of all other nephrotoxic drugs. Acute kidney injury (AKI) after HIPEC occurs in approximately 10–25% of patients — most recover fully with supportive care. Severe AKI requiring dialysis: approximately 1–3% of cases. |
| Pain Management | Epidural analgesia (thoracic or lumbar epidural catheter placed pre-operatively); Patient-controlled analgesia (PCA) with IV opioids as alternative; Paracetamol 1g every 6 hours IV as opioid-sparing adjuvant; Ketamine infusion in selected cases | Adequate pain control is essential after HIPEC to allow deep breathing, early mobilisation, and reduction of pulmonary complications. An epidural catheter placed before surgery provides excellent abdominal and thoracic pain control — significantly reducing opioid requirements and associated ileus. Good pain control → earlier extubation → earlier mobilisation → fewer pulmonary complications. |
| Gastrointestinal Recovery (Ileus Management) | Nasogastric tube (NGT) drainage; NGO (nil by mouth) for 24–72 hours; Gradual diet advancement: clear fluids → soft diet → normal diet; Prokinetic agents (metoclopramide, erythromycin) if ileus prolonged; Early mobilisation from day 2–3 | Prolonged post-operative ileus (bowel paralysis) is one of the most common HIPEC complications — occurring in approximately 30–50% of patients. Most ileus resolves within 5–7 days. Nasogastric decompression prevents dangerous bowel distension. If ileus persists beyond 7 days — CT imaging to exclude anastomotic leak or mechanical obstruction. |
| Respiratory Management | Chest physiotherapy from day 1; Incentive spirometry; High-flow oxygen supplementation; Continuous pulse oximetry; Chest X-ray on day 1 and as clinically indicated; Pleural effusion drainage (Interventional Radiology) if significant | The diaphragm has been manipulated during CRS (diaphragm stripping/resection is common in advanced ovarian HIPEC). Post-operatively, splinting the diaphragm leads to basal atelectasis and pleural effusions. Aggressive physiotherapy, adequate analgesia, and early sitting-up are the cornerstones of respiratory management. LMWH prophylaxis is mandatory from the first post-operative day for DVT/PE prevention. |
| Haematological Monitoring | Daily FBC: haemoglobin, white cell count, platelet count; Blood transfusion threshold: Hb <7–8 g/dL; LMWH DVT prophylaxis from day 1; G-CSF if neutropenia develops (<1.0 × 10⁹/L) | Cisplatin causes bone marrow suppression — the nadir of white blood cell count occurs at 10–14 days post-HIPEC. Severe neutropenia (<0.5 × 10⁹/L) requires protective isolation and growth factor support (G-CSF). Febrile neutropenia (neutropenia + fever) requires urgent broad-spectrum antibiotics. |
| Nutritional Support | Early enteral nutrition (via NGT/NJ tube) within 24–48 hours where possible; Total parenteral nutrition (TPN) if prolonged ileus prevents enteral feeding; Dietitian involvement from day 1; Target 25–30 kcal/kg/day; Protein supplementation 1.2–1.5 g/kg/day | HIPEC patients are nutritionally depleted from cancer and chemotherapy before surgery. Post-operatively, the metabolic demand of healing from major surgery creates a highly catabolic state. Adequate nutritional support — preferably enteral (through the gut) — is essential for wound healing, immune function, and recovery. Albumin replacement may be needed if serum albumin falls below 25g/L. |
| Cost Component | Amount (₹) | Details and Notes |
|---|---|---|
| Cytoreductive Surgery (CRS) — Surgical Package (Group I Complex) | Economy Room: ₹4,07,564 Twin Sharing: ₹5,70,590 Single Room: ₹7,13,237 ICU Suite: ₹12,94,525 | These are the official 2026 Shree Hospitals surgical package figures. The CRS package covers: surgeon's fees, OT + gas charges, anaesthesia fees, assistant surgeon fees, and CSSD (sterilisation). Multivisceral cytoreductive surgery is categorised as Group I Complex due to the extensive multi-organ dissection, the number of procedures performed simultaneously, and the prolonged operative time (6–12+ hours). |
| HIPEC Perfusion Component (Additional — Above the CRS Package) | ₹2,00,000–4,00,000 additional (₹2–4 Lakhs) Separate from the CRS package | The HIPEC component charges cover: Use of the HIPEC perfusion machine and dedicated pump circuit; HIPEC-specific single-use disposable perfusion catheters and circuit tubing; Cisplatin (100 mg/m² — the HIPEC drug — at approximately ₹15,000–30,000 per session depending on body surface area); Perfusionist team time during the 90-minute perfusion; Specialist anaesthetic monitoring team during HIPEC phase. |
| TOTAL — India (Shree Hospitals) | ₹10–20 Lakhs | All-inclusive estimate covering CRS package + HIPEC perfusion component + ICU stay + standard post-operative care. Individual cases may vary. Verify with Shree Hospitals billing team before admission. |
| USA | ₹80–1.40 Crore ($96,000–170,000) | India offers equivalent HIPEC surgical quality — when performed by an experienced peritoneal oncosurgeon team like Dr. Gandhi, Dr. Burde and Dr. Mehta at Shree Hospitals — at 85–92% lower cost than the USA. The cost advantage is structural and does not reflect any difference in clinical protocol, surgical quality, or post-operative ICU standards. |
| Singapore | ₹30–60 Lakhs (SGD$52,000–103,000) | |
| UK (Private) | ₹45–80 Lakhs (£43,000–77,000) |
Insurance and Financing for HIPEC
Pre-authorisation: Contact your insurance company BEFORE admission with a letter of medical necessity from Dr. Gandhi, Dr. Burde and Dr. Mehta. Pre-authorisation significantly improves claim success rates. EMI options: Bajaj Finserv Health EMI Card (0% interest for 3–12 months), Tata Capital medical loans, and bank medical loans are all available. Ayushman Bharat PMJAY: Check eligibility at the Shree Hospitals PMJAY desk — cancer surgery is covered and HIPEC may fall within eligible packages. Online pre-consultation (FREE): Call +91-9920914115 to arrange an online video assessment — preliminary eligibility and cost estimate without travelling to Mumbai.
Transparency about risk is not a reason to avoid HIPEC — it is a reason to choose the most experienced team available. The institutional experience of the surgical and ICU team is the single most important determinant of HIPEC complication rates.
| Risk / Complication | Frequency | Management and Clinical Significance |
|---|---|---|
| Prolonged Ileus (Bowel Paralysis) | 30–50% of cases | The most common post-HIPEC complication. The bowel temporarily stops working after the combination of heat, chemical exposure, and surgical handling. A nasogastric tube drains the accumulated fluid. Most ileus resolves within 5–7 days with supportive care. If prolonged beyond 7 days or worsening — CT scan to exclude anastomotic leak or obstruction. |
| Acute Kidney Injury (Cisplatin Nephrotoxicity) | 10–25% of cases; Dialysis-requiring in 1–3% | Cisplatin directly damages kidney tubules. Preventable with aggressive pre- and intra-operative hydration, urinary alkalinisation, and avoidance of nephrotoxic drugs. Serial daily creatinine monitoring. Most AKI is reversible with aggressive fluid management. Permanent renal impairment is rare but possible in severe cases. |
| Anastomotic Leak (If Bowel Resection Performed) | 5–15% when bowel resection included | When a segment of bowel is removed and the ends are joined (anastomosis), the join may break down — allowing bowel contents to leak into the abdominal cavity. This is a serious complication requiring re-operation or interventional radiology drainage. Drain fluid is monitored daily — elevated drain amylase is an early warning sign. |
| Haematological Toxicity (Bone Marrow Suppression) | Neutropenia: 20–40%; Thrombocytopenia: 10–25% | Cisplatin suppresses bone marrow production of white blood cells and platelets. Nadir at 10–14 days post-HIPEC. Severe neutropenia (<0.5 × 10⁹/L) requires protective isolation and growth factor support (G-CSF). Febrile neutropenia (neutropenia + fever) requires urgent broad-spectrum antibiotics. |
| Wound Complications (Dehiscence, Infection) | Wound infection: 10–15%; Dehiscence: 3–5% | The large HIPEC laparotomy incision is vulnerable to infection and wound breakdown — due to the combination of malnutrition, immunosuppression, duration of surgery, and potential chemical exposure from HIPEC drugs. Aggressive nutritional support, mass closure technique, and prophylactic antibiotics reduce risk. |
| Pulmonary Complications (Pleural Effusion, Atelectasis, PE) | Pleural effusion: 20–30%; Significant PE: 1–3% | Diaphragm stripping during CRS impairs post-operative breathing. Protein loss causes pleural effusion formation. Chest physiotherapy and adequate analgesia are critical. Large pleural effusions may require interventional radiology drainage. DVT and PE risk is elevated in cancer patients undergoing major surgery — LMWH prophylaxis is mandatory. |
| Mortality Risk | Perioperative mortality: 1–3% at experienced centres; Higher at inexperienced centres | HIPEC mortality at high-volume expert centres is approximately 1–3% — equivalent to or lower than other major abdominal oncological procedures. At low-volume or inexperienced centres, mortality risk is significantly higher. This is the single strongest argument for concentrating HIPEC in specialised, high-volume centres like Shree Hospitals. |
| Long-Term Toxicity (Post-Discharge) | Neuropathy: 20–30%; Ototoxicity: 5–15% | Cisplatin can cause peripheral neuropathy (tingling, numbness in hands and feet) and ototoxicity (high-frequency hearing loss). These effects develop over weeks to months after HIPEC. Neuropathy is typically reversible over 6–12 months; ototoxicity may be permanent. Patients are counselled about these risks before HIPEC. |
| Clinical Excellence Factor | Why It Matters for Your HIPEC Surgery |
|---|---|
| Dr. Amit Ratan Gandhi — Peritoneal Oncosurgeon (HIPEC Programme Lead) | Dr. Amit Ratan Gandhi is an advanced pelvic surgeon with specific expertise in cytoreductive surgery (CRS) and HIPEC — one of the most technically demanding surgical disciplines in all of oncology. He leads the Gynecologic Oncosurgery team at Shree Hospitals. CRS + HIPEC requires a surgeon experienced in: complete peritoneal stripping, bowel resection and reanastomosis, diaphragm stripping and resection, and the management of the HIPEC perfusion circuit intraoperatively. |
| Dr. Kaustubh Burde + Dr. Jay Mehta — Combined Expertise | Dr. Kaustubh Burde's advanced pelvic surgery training and peritoneal oncology expertise, combined with Dr. Jay Mehta's MCH Gynecologic Oncology leadership, creates a two-surgeon team with complementary skills — the standard for high-quality HIPEC centres globally, where a peritoneal surgeon and a gynecologic oncologist operate together on complex ovarian cancer cases. |
| Tertiary Level ICU — 24-Hour Consultant Intensivist Coverage | HIPEC surgery is not complete at the time the abdomen is closed. The next 7–14 days of post-operative ICU management are as important to the patient's outcome as the surgery itself. Shree Hospitals operates a fully equipped, consultant-staffed tertiary ICU with: 24-hour intensivist availability; advanced haemodynamic monitoring; full ventilatory support capability; renal replacement therapy (dialysis) when needed for severe cisplatin AKI; specialist ICU nursing team. |
| In-House MRI and Advanced Radiology | Pre-operative assessment of HIPEC eligibility requires high-resolution peritoneal imaging to estimate PCI and identify the distribution of disease. At Shree Hospitals, in-house MRI provides: dedicated pelvic and abdominal MRI for HIPEC pre-operative staging; diffusion-weighted imaging (DWI-MRI) for peritoneal disease quantification and PCI estimation; post-operative MRI for detecting residual disease, complication assessment, or recurrence surveillance. |
| Interventional Radiology Backup (24/7) | Shree Hospitals has a dedicated 24/7 Interventional Radiology (IR) department: ultrasound-guided drainage of post-operative collections (anastomotic leak, infected haematoma, ascites) — avoids re-laparotomy; percutaneous drain placement for pleural effusions; vascular interventions for managing post-surgical haemorrhage. The availability of IR as a first-line resource for post-operative complications materially reduces HIPEC-related morbidity and mortality. |
| Complete Surgical Spectrum + Robotic Surgery | Shree Hospitals provides the complete spectrum of ovarian cancer surgical treatment — from diagnostic laparoscopy and laparoscopic staging, through standard open cytoreductive surgery, to robotic-assisted procedures and the full HIPEC capability. Robotic-assisted assessment laparoscopy is available to evaluate resectability before committing to open CRS + HIPEC. |
| Pan-India Access — Online Consultations | Women diagnosed with Stage III ovarian cancer in other states — Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, Andhra Pradesh, Karnataka, and beyond — regularly travel to Shree Hospitals for HIPEC assessment and surgery. The Shree Hospitals Gynecologic Oncology team offers online video consultations with Dr. Jay Mehta and Dr. Kaustubh Burde for HIPEC eligibility assessment — reviewing staging CT/MRI, CA-125 response to NACT, surgical history, and performance status without the need to travel to Mumbai for an initial review. |
Discuss HIPEC Eligibility — India's Most Experienced HIPEC Team
Dr. Amit Ratan Gandhi, Dr. Jay Mehta & Dr. Kaustubh Burde at Shree Hospitals, Mumbai provide online HIPEC eligibility assessments for patients from across India — reviewing staging CT, MRI, CA-125 response, and NACT history without you needing to travel to Mumbai for an initial review. HIPEC may be the most important treatment decision in your ovarian cancer journey. It deserves the most experienced team.
Frequently Asked Questions — HIPEC for Ovarian Cancer in India
⚠️ HIPEC and Ovarian Cancer — These Situations Require Specialist Discussion Immediately
Contact Dr. Amit Ratan Gandhi, Dr. Jay Mehta and Dr. Kaustubh Burde at Shree Hospitals today if any of these apply to you:
- You have been diagnosed with Stage III ovarian cancer and your surgeon has NOT discussed HIPEC as part of your treatment plan — ask specifically whether HIPEC is appropriate for you
- You have been told you need ovarian cancer debulking surgery at a centre that does NOT have HIPEC capability — consider whether a HIPEC-capable centre is accessible for your care
- You are receiving neoadjuvant chemotherapy (NACT) for ovarian cancer and approaching interval debulking surgery — this is the ideal moment to discuss HIPEC eligibility with your oncosurgeon
- You have completed cytoreductive surgery but HIPEC was not performed — this does not automatically mean you missed the opportunity; second-look surgery with HIPEC may be discussed in selected cases
- Your CA-125 has declined dramatically after NACT (suggesting excellent chemotherapy response) — this is a strong predictor of eligibility for HIPEC at interval debulking surgery
- You have recurrent ovarian cancer being considered for secondary cytoreduction — HIPEC at secondary cytoreduction may be discussed in selected cases at specialist centres
- You are travelling from another city or state for ovarian cancer surgery — Shree Hospitals provides pre-operative online consultation with Dr. Jay Mehta and Dr. Kaustubh Burde to assess HIPEC eligibility before you make the journey to Mumbai
Department of Gynecologic Oncology | Shree Hospitals, Mumbai
📞 +91-9920914115 | Toll-Free: 18002684000
✅ HIPEC-Capable Centre ✅ Tertiary ICU ✅ In-House MRI ✅ Interventional Radiology Backup ✅ Gynec Oncology + Robotic Surgery
Clinical Case Studies: HIPEC in Practice at Shree Hospitals
The following case studies illustrate how HIPEC eligibility assessment and execution works in real clinical scenarios at Shree Hospitals — and the clinical reasoning that guides the decision to proceed with HIPEC in each case.
Priya, 48, from Pune. Diagnosed with Stage IIIC high-grade serous epithelial ovarian cancer. CT staging: peritoneal deposits on omentum, bowel surface, diaphragm, and pelvic sidewalls. PCI estimated at 12–14 on DWI-MRI. CA-125 at diagnosis: 1,840 U/ml. She received 3 cycles of carboplatin + paclitaxel (NACT). Response assessment CT: dramatic tumour regression. CA-125 fell to 38 U/ml — a 98% reduction from baseline.
HIPEC Assessment at Shree Hospitals
Dr. Jay Mehta and Dr. Kaustubh Burde reviewed Priya's staging CT and NACT response imaging in a joint consultation. The CA-125 fall from 1,840 to 38 U/ml, combined with the CT response showing near-complete clearance of the omental disease and significant reduction in diaphragmatic deposits, strongly predicted achievable CC-0 at interval debulking surgery. Diagnostic laparoscopy performed 2 weeks before surgery confirmed: PCI at laparoscopy = 8. Complete cytoreduction highly likely. Decision: proceed with CRS + HIPEC at interval debulking surgery.
Surgery
Dr. Amit Ratan Gandhi (lead peritoneal surgeon) + Dr. Kaustubh Burde performed the cytoreductive surgery: total abdominal hysterectomy + bilateral salpingo-oophorectomy + total omentectomy + peritoneal stripping (pelvic sidewalls, diaphragm) + appendicectomy. Total CRS time: 6.5 hours. CC score at end of CRS: CC-0 (no visible residual disease). HIPEC proceeded: cisplatin 75 mg/m² at 42°C for 90 minutes. Abdominal washout. Closure.
Sunita, 55, from Bengaluru. Stage IIIC ovarian cancer. Received 3 cycles of NACT with moderate CA-125 response (fall from 980 to 180 U/ml — 82% reduction). CT response: partial regression. PCI estimated at 16–18 on MRI. Diagnostic laparoscopy at Shree Hospitals: intraoperative PCI = 20. Small bowel disease more extensive than anticipated on imaging. Complete cytoreduction assessed as uncertain.
The Intraoperative Decision
Dr. Amit Ratan Gandhi commenced cytoreductive surgery. After total hysterectomy, BSO, omentectomy, and peritoneal stripping — the small bowel surface disease proved more extensive than the pre-operative assessment suggested. Despite extensive bowel resection (two segments, two anastomoses), residual disease of 3–5mm nodules remained on the small bowel mesentery (CC-1/CC-2 borderline). An intraoperative team discussion — standard practice at Shree Hospitals — concluded that proceeding with HIPEC at CC-1/2 would not provide meaningful benefit and would expose Sunita to the full toxicity profile of cisplatin-HIPEC without the expected survival benefit. Decision: HIPEC abandoned. Surgery completed without HIPEC.
Kavita, 38, from Delhi. Stage IIIC high-grade serous epithelial ovarian cancer. Diagnosed at 38 years old — unmarried at the time of diagnosis. No children. CA-125: 3,200 U/ml. CT: extensive omental cake, pelvic peritoneal disease, diaphragmatic deposits bilaterally. Before starting NACT, Kavita requested a discussion about fertility preservation options with Dr. Jay Mehta.
Fertility Preservation Before NACT
Dr. Mehta confirmed: at Stage IIIC, bilateral oophorectomy will be required as part of cytoreductive surgery for HIPEC. Natural fertility after HIPEC is not possible. However — before NACT begins, if Kavita wishes to preserve future family-building options, egg or embryo freezing can be attempted in the window before the first chemotherapy cycle. This was discussed honestly: ovarian stimulation for egg freezing takes 10–14 days; NACT must not be delayed significantly; the cancer is the medical priority. Kavita chose to proceed with emergency egg freezing at Shree IVF Clinic (coordinated by Dr. Mehta's team) before her first cycle of NACT — retrieving 9 eggs, 7 mature, 5 frozen (2-pronuclear zygotes also frozen). NACT commenced 16 days after egg retrieval.
Glossary — Every HIPEC Term Explained
- HIPEC (Hyperthermic Intraperitoneal Chemotherapy)
- A specialised cancer treatment in which heated chemotherapy solution (typically cisplatin at 41–43°C) is circulated directly through the abdominal cavity immediately after all visible cancer has been surgically removed. Delivers 10–1,000× higher drug concentration at the peritoneal surface compared to IV chemotherapy.
- CRS (Cytoreductive Surgery)
- Surgical procedure performed before HIPEC — systematically removing all visible cancer deposits from the abdominal cavity. Also called 'debulking surgery.' The completeness of CRS is the single most important determinant of HIPEC outcome.
- CC Score (Completeness of Cytoreduction Score)
- A standardised assessment of residual disease after CRS. CC-0: no visible residual disease (ideal). CC-1: residual nodules ≤2.5mm (acceptable for HIPEC at experienced centres). CC-2 and CC-3: significant residual disease — HIPEC should generally not be performed.
- PCI (Peritoneal Carcinomatosis Index)
- A standardised scoring system (0–39) developed by Dr. Paul Sugarbaker to quantify the extent of peritoneal cancer spread. Lower PCI = more likely to achieve complete cytoreduction = more likely to benefit from HIPEC. PCI ≤10–15 is most favourable; PCI >20 often precludes complete cytoreduction.
- Peritoneum
- The thin tissue layer that lines the inner wall of the abdomen and most of the abdominal organs. Ovarian cancer spreads primarily along the peritoneum — forming microscopic cancer deposits on peritoneal surfaces. HIPEC specifically targets these peritoneal deposits.
- Peritoneal-Plasma Barrier
- The physiological barrier that limits how much chemotherapy from the bloodstream can enter the peritoneal cavity. Standard IV chemotherapy reaches the peritoneum at relatively low concentrations because of this barrier. HIPEC bypasses it entirely by delivering chemotherapy directly into the peritoneal cavity.
- NACT (Neoadjuvant Chemotherapy)
- Chemotherapy given BEFORE surgery — to reduce tumour size and make complete cytoreduction more achievable. Typically 3 cycles of carboplatin + paclitaxel in ovarian cancer. Interval debulking surgery (IDS) + HIPEC after NACT is the context validated by the OVHIPEC-1 trial.
- IDS (Interval Debulking Surgery)
- Cytoreductive surgery performed after neoadjuvant chemotherapy — the context in which HIPEC has the strongest evidence base (OVHIPEC-1 trial). NACT shrinks the tumour burden, making complete cytoreduction more achievable at IDS than at primary surgery.
- PDS (Primary Debulking Surgery)
- Cytoreductive surgery performed WITHOUT any prior chemotherapy — the first treatment approach. HIPEC at PDS is being studied in the OVHIPEC-2 trial (results awaited). Currently the evidence base for HIPEC is strongest at IDS.
- Cisplatin Nephrotoxicity
- Direct toxic damage to kidney tubules caused by cisplatin — the most important organ-specific risk of cisplatin-HIPEC. Prevention: aggressive IV hydration, urinary alkalinisation, and avoidance of nephrotoxic drugs. AKI after HIPEC occurs in approximately 10–25% of patients — most recover fully with supportive care.
- Hyperthermia (in HIPEC)
- The use of elevated temperature (41–43°C) in HIPEC to: directly kill cancer cells by denaturing proteins; enhance drug penetration into tumour tissue; and increase the sensitivity of cancer cells to chemotherapy damage. Heat is an independent anti-tumour mechanism in addition to the chemotherapy itself.
- OVHIPEC-1 Trial
- The landmark clinical trial (van Driel et al., New England Journal of Medicine, 2018) that established HIPEC as a valid option for Stage III ovarian cancer. HIPEC at interval debulking surgery extended median overall survival by approximately 12 months (45.7 vs 33.9 months) without significantly increasing serious complications. Changed practice internationally.
- PARP Inhibitor
- A targeted maintenance therapy used after completion of chemotherapy in BRCA-positive ovarian cancer (olaparib/Lynparza, niraparib/Zejula). Started approximately 4–6 weeks after the last chemotherapy cycle — which is usually 12–16 weeks after HIPEC surgery. Significantly extends progression-free survival in BRCA-positive, HRD-positive patients.
- Anastomotic Leak
- A complication that occurs when a bowel anastomosis (the surgical join between two segments of bowel, after a section of bowel was removed) breaks down — allowing bowel contents to leak into the abdominal cavity. Occurs in 5–15% of HIPEC cases where bowel resection was performed. Drain fluid amylase is monitored as an early warning sign.
- G-CSF (Granulocyte Colony-Stimulating Factor)
- A drug (filgrastim/Neupogen) that stimulates bone marrow to produce more white blood cells — used when cisplatin causes severe neutropenia (low white blood cells) after HIPEC. Reduces the duration and severity of neutropenia and the associated infection risk.
- Ileus
- Temporary paralysis or cessation of bowel activity — one of the most common complications of HIPEC (30–50% of cases). Caused by the combination of heat, chemical exposure, bowel handling during CRS, and opioid analgesics. Most ileus resolves within 5–7 days with nasogastric decompression, prokinetics, and early mobilisation.
© Department of Gynecologic Oncology, Shree Hospitals. All rights reserved. Content may not be reproduced without written permission.
